Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

<p>Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.</p>

Saved in:

Bibliographic Details
Main Author:	Filip Stanicic (17808254) (author)
Other Authors:	Vladimir Zah (5151461) (author), Dimitrije Grbic (17808257) (author), Djurdja Vukicevic (9291181) (author), Debra de Angelo (21728800) (author)
Published:	2025
Subjects:	Medicine Neuroscience Pharmacology Biotechnology Developmental Biology Cancer Mental Health Infectious Diseases traumatic stress disorder showed consistent improvements provided qualitative synthesis group statistical assessments demonstrate sustained effects beck depression inventory demonstrated significant improvement xlink "> overall xlink "> fda xlink "> 3 psychotherapy trials lacked higher severity treatment higher severity ptsd administered ptsd scale three interventional sessions mean duration 6 label medications used higher severity post 7 &# 8211 significant caps improvement current treatment options ptsd treatment guidelines xlink "> mdma ii score compared studies observing chronic point caps decrease populations included adults xlink "> mean duration caps improvement point decrease ptsd treatment three active sessions ranged phase ii current treatments controlled trials included studies 77 studies venlafaxine er term follow primary outcome investigational mdma heterogeneous evidence evidence presented dose mdma december 20 comprehensive summary comparators based assess risk
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items